A placebo‐controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis

Bade, Jj; Laseur, M.; Nieuwenburg, A.; Weele, L T van der; Mensink, H. J. A.

doi:10.1046/j.1464-410x.1997.03384.x

Cited by 108 publications

(57 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bade et al observed improvement in symptoms for 40% of patients compared to placebo, with rare hematuria reported as the only adverse event. 158 Davis et al obtained a 62% response rate at Week 18 for patients treated with both oral and intravesical PPS compared to oral PPS and intravesical NS, with no significant differences in adverse events between treatment groups. 159 Finally, in an open-label, uncontrolled study, intravesical PPS encapsulated into liposomes showed efficacy and safety in eight patients over three months.…”

Section: Bacillus Calmette-guerin (Bcg) (Not Recommended Grade B)mentioning

confidence: 99%

CUA guideline: Diagnosis and treatment of interstitial cystitis/ bladder pain syndrome

Cox

Golda

Nadeau

et al. 2016

CUAJ

113

121

View full text Add to dashboard Cite

MethodologyThe following guidelines were based on MEDLINE and PUBMED searches of English language literature, in addition to consensus conference proceedings. Levels of evidence and grades of recommendation were assigned for each investigation and treatment, as per the modified Oxford Centre for Evidence-Based Medicine grading system. Where the literature was inconsistent or scarce, a consensus expert opinion was generated to provide treatment guidelines.

show abstract

Section: Bacillus Calmette-guerin (Bcg) (Not Recommended Grade B)mentioning

confidence: 99%

CUA guideline: Diagnosis and treatment of interstitial cystitis/ bladder pain syndrome

Cox

Golda

Nadeau

et al. 2016

CUAJ

113

121

View full text Add to dashboard Cite

show abstract

“…The closest results on efficacy were observed with intravesical PPS [37] and a combination of intravesical plus oral PPS [38]; this last combined strategy reported by Davis et al [38], however, showed a higher RR in patients who received oral PPS alone (90 vs 85.7 %).…”

Section: Discussionmentioning

confidence: 86%

“…4. OR value was highest for HMW-HA in the Shao et al study [34], followed by the intravesical application of 300 mg of PPS described by Bade et al [37].…”

Section: Evaluation Of Efficacymentioning

confidence: 82%

“…The final set of 19 articles on intravesical BPS/IC therapy was further qualitatively and quantitatively analysed: 5 studies were prospective controlled trials [34][35][36][37][38], 1 compared different intravesical products [39], 1 paper was designed as a retrospective study [40], and another 1 compared two different regimens of the same product [41]. The rest of the trials were classified as uncontrolled clinical studies (Table 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review and Meta-analysis on the Efficacy of Intravesical Therapy for Bladder Pain Syndrome/Interstitial Cystitis

Barua

Arance

Angulo

et al. 2016

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

Bladder pain syndrome/interstitial cystitis (BPS/ IC) is a chronic disease characterised by persistent irritating micturition symptoms and pain. The objective was to compare the clinical efficacy of currently available products for intravesical therapy of BPS/IC and to assess their pharmacoeconomic impact. A Pubmed/Medline database search was performed for articles on intravesical therapy for BPS/IC. A total of 345 publications were identified, from which 326 were excluded. Statistical evaluation was performed with effect size (ES) assessment of symptom reduction and response rates. The final set of 19 articles on intravesical BPS/IC therapy included 5 prospective controlled trials (CTs), the remaining were classified as uncontrolled clinical studies. The total number of patients included was 801, 228 of whom had been evaluated in a CT. For CTs, the largest ES for symptom reduction as well as response rate was observed for high molecular weight hyaluronic acid (HMW-HA), with similar findings in two uncontrolled studies with HMW-HA. The number needed to treat to achieve a response to intravesical therapy was 2.67 for intravesical pentosan polysulphate and 1.31 for HMW-HA which were superior to all other instillates.HMW-HA was significantly superior in cost effectiveness and cost efficacy to all other instillation regimes. The present meta-analysis combined medical and pharmacoeconomic aspects and demonstrated an advantage of HMW-HA over other instillation agents; however, direct comparisons between the different products have not been performed to date in properly designed controlled studies.

show abstract

“…There have been at least five double-blind, placebocontrolled studies, all of which have demonstrated that 100 mg TID of PPS provides significant pain relief over placebo (42)(43)(44)(45)(46).…”

Section: Oral Medication Ppsmentioning

confidence: 99%

Interstitial cystitis: The great imposter! Epidemiology, etiology, diagnosis and management

Barkin¹

2003

J Sex Reprod Med

373

View full text Add to dashboard Cite

About 115 years ago, the first diagnosis of interstitial cystitis (IC) was offered as a reason to explain the pain related to scarring and inflammation in the bladder. Later, Hunner described the pathognomonic ulcer that bears his name, which is only found in about 5% to 10% of patients with IC. Today, IC is considered a controversial diagnosis. There are still a significant number of clinicians that do not believe in the diagnosis. Some people consider it to be only a diagnosis of exclusion -after every other bladder condition has been ruled out. However, population studies have demonstrated that there is a huge number of patients (mainly female) that fulfill the NIH and/or other diagnostic criteria and deserve the treatment for IC. Frequency, urgency and pain (pelvic and/or voiding) with negative urinary cultures should be considered IC and treated as such. Dyspareunia is one of the commonest complaints of the IC sufferer. The physical, sexual and emotional impact of delayed or misdiagnois of this condition can be devastating or even suicide-provoking in some patients. We now have some excellent, effective and safe intravesical and oral therapies that can provide major relief to a significant number of patients. Il y a environ 115 ans, on a posé le premier diagnostic de cystite interstitielle (CI) comme raison pour expliquer la douleur liée à la cicatrisation et à l'inflammation dans la vessie. Plus tard, Hunner a décrit l'ulcère pathognomonique qui porte son nom : il se manifeste seulement chez environ 5 % à 10 % des patients souffrant de CI. Aujourd'hui, le diagnostic de la CI est controversé. D'ailleurs, il reste encore de nombreux cliniciens qui ne croient pas à ce diagnostic. Pour certains, il s'agit seulement d'un diagnostic d'exclusion -soit après qu'on a éliminé toutes les autres conditions pouvant affecter la vessie. Cependant, des études sur la population ont démontré qu'un nombre très élevé de patients (principalement des femmes) répondent aux critères du NIH et/ou à d'autres critères de diagnostic et méritent de recevoir le traitement contre la CI. La fréquence des épisodes, l'urgence et la douleur (pelvienne et/ou lors de l'élimina-tion) accompagnées de cultures urinaires négatives devraient être associées à la CI et traitées en conséquence. La dyspareunie est l'une des plaintes les plus fréquentes émanant des personnes souffrant d'une CI. Les répercussions physiques, sexuelles et émotionnelles d'un diagnostic retardé ou d'un mauvais diagnostic de cette condition peuvent être dévas-tatrices entraînant même le suicide chez certains patients. Il existe maintenant des traitements intravésicaux et oraux qui peuvent procurer un soulagement majeur à un nombre important de patients. Key

show abstract

A placebo‐controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis

Cited by 108 publications

References 5 publications

CUA guideline: Diagnosis and treatment of interstitial cystitis/ bladder pain syndrome

CUA guideline: Diagnosis and treatment of interstitial cystitis/ bladder pain syndrome

A Systematic Review and Meta-analysis on the Efficacy of Intravesical Therapy for Bladder Pain Syndrome/Interstitial Cystitis

Interstitial cystitis: The great imposter! Epidemiology, etiology, diagnosis and management

Contact Info

Product

Resources

About